Mitochondrial Diseases clinical trials at UCSD
2 research studies open to eligible people
KL1333 in Adult Patients With Primary Mitochondrial Disease
open to eligible people ages 18 years and up
The primary objective of the FALCON study is to evaluate the efficacy of KL1333 on selected disease manifestations of primary mitochondrial disease (PMD) following 48 weeks of treatment. This objective involves evaluating the efficacy of KL1333 versus placebo on fatigue symptoms and impacts on daily living as well as on functional lower extremity strength and endurance. Additionally, the study evaluates the safety and tolerability of KL1333.
San Diego, California and other locations
North American Mitochondrial Disease Consortium Patient Registry and Biorepository (NAMDC)
open to all eligible people
The North American Mitochondrial Disease Consortium (NAMDC) maintains a patient contact registry and tissue biorepository for patients with mitochondrial disorders.
San Diego, California and other locations
Our lead scientists for Mitochondrial Diseases research studies include Richard Haas, MD PhD.
Last updated: